Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts
Abstract
Active surveillance (AS) is an accepted means of managing low‐risk prostate cancer. Because of the rarity of downstream events, data from existing AS cohorts cannot yet address how differences in surveillance intensity affect metastasis and mortality. This study projected the comparative benefits of different AS schedules in men diagnosed with prostate cancer who had Gleason score (GS) ≤6 disease and risk profiles similar to those in North American AS cohorts.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 22, 2019
- Source ID
- 10.1002/cncr.32557
Entities
People
- Aaron A. Laviana
- Anna Bill‐axelson
- Bruce J Trock
- Daniel W Lin
- David F. Penson
- H. Ballentine Carter
- Jane M Lange
- Janet E Cowan
- Laurence H. Klotz
- Lisa F. Newcomb
- Mathew R. Cooperberg
- Peter R. Carroll
- Ruth Etzioni
- Sigrid V. Carlsson
Organizations
- Canary Foundation
- Fred Hutchinson Cancer Center
- Genomic Health
- Johns Hopkins School of Medicine
- Johns Hopkins University
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- Prostate Cancer Canada
- Swedish Cancer Society
- United States Agency for Healthcare Research and Quality
- United States Department of Defense
- University of California, San Francisco
- University of Gothenburg
- University of Toronto
- University of Washington
- Uppsala University
- Vanderbilt University